Pathologic Response and Survival After Neoadjuvant Immunotherapy for Resectable Mucosal HNSCC
Study findings suggest that overall PPR and MPR are associated with improved DFS. These data provide additional support for the potential use of pathologic treatment response as a surrogate for DFS after neoadjuvant ICI in resectable mucosal HNSCC.
Authors
- Eric V. Mastrolonardo (ORCID: https://orcid.org/0000-0002-2869-8848)
- Joseph Curry (ORCID: https://orcid.org/0000-0001-9507-4237)
- Scott Koeneman (ORCID: https://orcid.org/0000-0001-9928-5330)
- Richard Andrew Goldman (ORCID: https://orcid.org/0009-0006-5353-1077)
- Jason Tasoulas (ORCID: https://orcid.org/0000-0003-3791-3252)
- Christopher Fundakowski
- Kelly Bridgham (ORCID: https://orcid.org/0000-0001-7043-0602)
- Emma De Ravin (ORCID: https://orcid.org/0000-0002-1076-1941)
- Jennifer M. Johnson (ORCID: https://orcid.org/0000-0003-4548-307X)
- Arielle G. Thal (ORCID: https://orcid.org/0000-0002-7498-8512)
- David M. Cognetti (ORCID: https://orcid.org/0000-0001-7039-3055)
- Hannah Kenny (ORCID: https://orcid.org/0000-0002-2652-9418)
- Leonard E. Estephan (ORCID: https://orcid.org/0000-0001-9599-1510)
- Praneet C. Kaki (ORCID: https://orcid.org/0009-0005-6428-2064)
- Kathryn Nunes (ORCID: https://orcid.org/0009-0003-3657-978X)
- Adam J. Luginbuhl
Institutions
- Thomas Jefferson University (US)
- Sidney Kimmel Cancer Center (US)
Publication Details
- Journal
- JAMA Otolaryngology–Head & Neck Surgery
- Published
- 2025-12-18
- DOI
- https://doi.org/10.1001/jamaoto.2025.4573
- Citations
- 1
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 1.32